阿斯利康将向许可方支付合计12亿美元的总首付款，其中巨石生物收取的首付款金额为总首付款金额的 35%。阿斯利康将根据许可区域范围内的开发、上市和销售等情况，向许可方支付相应里程碑款项。阿 斯利康将向许可方累计支付最高35亿美元的开发里程碑款项、最高138亿美元的销售里程碑款项。其 中，巨石生物将有权根据《战略合作与授权协议》所授权管线的实际情况收取相应的开发里程碑款项和 销售里程碑款项。 本次交易有利于加快公司相关创新药管线在全球范围内的开发和商业化进程，对公司深化全球布局、加 速创新成果转化具有重要意义。本次交易将持续优化公司现金流结构，加速前期研发投入回收，为后续 创新药管线的持续研发提供稳定的资金支持，高度契合公司加速打造领先的创新生物医药平台的长期发 展战略，有利于促进公司的长远可持续发展，对公司的未来经营发展将产生较大的积极影响。 新诺威（300765）(300765.SZ)发布公告，公司的控股子公司石药集团巨石生物制药有限公司(以下简 称"巨石生物")及公司的关联方石药集团有限公司(以下简称"石药集团")、石药集团中奇制药技术(石家 庄)有限公司(以下简称"中奇制药")共同与阿斯利康于2026年1 ...

本次交易有利于加快公司相关创新药管线在全球范围内的开发和商业化进程，对公司深化全球布局、加 速创新成果转化具有重要意义。本次交易将持续优化公司现金流结构，加速前期研发投入回收，为后续 创新药管线的持续研发提供稳定的资金支持，高度契合公司加速打造领先的创新生物医药平台的长期发 展战略，有利于促进公司的长远可持续发展，对公司的未来经营发展将产生较大的积极影响。 智通财经APP讯，新诺威(300765.SZ)发布公告，公司的控股子公司石药集团巨石生物制药有限公司(以 下简称"巨石生物")及公司的关联方石药集团有限公司(以下简称"石药集团")、石药集团中奇制药技术 (石家庄)有限公司(以下简称"中奇制药")共同与阿斯利康于2026年1月29日签署《战略合作与授权协 议》，将与阿斯利康在创新多肽分子发现和长效递送产品的开发领域开展全面战略合作。 巨石生物与石药集团、中奇制药共同作为许可方，将与阿斯利康在创新多肽分子发现和长效递送产品的 开发领域开展全面战略合作。阿斯利康将获得许可方基于所拥有的长效递送技术平台及多肽药物发现平 台开发的创新长效多肽药物，包括一个临床准备就绪的项目SYH2082(长效GLP1R/GIPR激 ...

石药集团(01093)发布公告，集团已与全球生物制药领导者阿斯利康签订战略研发合作与授权协议，以 利用集团专有的缓释给药技术平台及多肽药物AI发现平台("该等平台")，开发创新长效多肽药物。 集团的长效技术可实现多肽药物的缓释，使给药间隔达到每月一次或更长。基于此平台开发的产品为即 用型，使用简便，支持患者自行给药，能有效提升长期用药人群的治疗依从性。同时，集团的多肽药物 AI发现平台可以针对药物靶点快速设计及筛选候选分子，并可在药效、选择性与信号偏向性等维度进 行系统优化。 根据该协议的条款，集团将与阿斯利康在创新多肽分子的发现和长效递送产品的开发方面开展全面战略 合作。除持续推进现有临床前长效多肽管线之外，集团亦将为阿斯利康发现和开发其他创新长效多肽产 品。 除中国内地、中国香港、中国澳门及中国台湾外，阿斯利康将获得集团每月一次注射用体重管理产品组 合的全球独家权利，包括一个临床准备就绪的项目SYH2082(长效GLP1R/GIPR激动剂，正推进至I期临 床)，以及三个处于临床前阶段、具备不同作用机制的研发项目，旨在为肥胖及体重问题相关人群提供 更持久的治疗获益，双方还将依托该等平台就另外四个新增项目开展 ...

除中国内地、中国香港、中国澳门及中国台湾外，阿斯利康将获得集团每月一次注射用体重管理产品组 合的全球独家权利，包括一个临床准备就绪的项目SYH2082(长效GLP1R/GIPR激动剂，正推进至I期临 床)，以及三个处于临床前阶段、具备不同作用机制的研发项目，旨在为肥胖及体重问题相关人群提供 更持久的治疗获益，双方还将依托该等平台就另外四个新增项目开展合作。 格隆汇1月30日丨石药集团(01093.HK)发布公告，集团已与全球生物制药领导者阿斯利康签订战略研发 合作与授权协议，以利用集团专有的缓释给药技术平台及多肽药物AI发现平台("该等平台")，开发创新 长效多肽药物。集团的长效技术可实现多肽药物的缓释，使给药间隔达到每月一次或更长。基于此平台 开发的产品为即用型，使用简便，支持患者自行给药，能有效提升长期用药人群的治疗依从性。同时， 集团的多肽药物AI发现平台可以针对药物靶点快速设计及筛选候选分子，并可在药效、选择性与信号 偏向性等维度进行系统优化。 根据该协议的条款，集团将与阿斯利康在创新多肽分子的发现和长效递送产品的开发方面开展全面战略 合作。除持续推进现有临床前长效多肽管线之外，集团亦将为阿斯利康发现 ...

Core Viewpoint - The article highlights significant developments in the healthcare sector, particularly focusing on recent strategic partnerships and acquisitions involving major companies in the industry, showcasing the growing recognition and investment in innovative medical technologies. Group 1: Major Acquisitions and Collaborations - AstraZeneca has agreed to acquire a 50% stake in the development and commercialization rights of C-CAR031 in China from Westaim Biotech for up to $630 million, marking one of the largest licensing deals in the GPC3 CAR-T field to date [2][3][4] - Insilico Medicine has entered into a strategic drug development collaboration with Qilu Pharmaceutical, with a total contract value exceeding HKD 931 million, focusing on small molecule inhibitors for cardiovascular and metabolic diseases [6][7] - JingTai Technology has signed a strategic cooperation agreement with Dongyang Sunshine Pharmaceutical, aiming to establish a joint venture to leverage AI and robotics in drug development, with an expected investment of several hundred million yuan [17][18] Group 2: Clinical and Technological Advancements - C-CAR031, a CAR-T cell therapy targeting GPC3, has shown promising clinical results with an objective response rate of 56.5% and a disease control rate of 91.3% [4] - Shukun Technology has received 20 international certifications, including 15 EU MDR CE certifications and 3 FDA certifications, becoming one of the Chinese medical AI companies with the most international recognitions [9][10] - Lepu Medical's ScienCrown® valve system has successfully completed its first overseas implantations in Chile, marking a significant step in the global expansion of Chinese heart valve solutions [13][14][15] Group 3: Investment Landscape - Sequoia China has invested in over 200 healthcare companies with distinct technological features and high growth potential, covering various sectors including innovative drugs, medical devices, and digital healthcare, with more than 45 companies having completed IPOs in major stock markets [20]

（股份代號：1093） （於香港註冊成立之有限公司） 自願公告 與阿斯利康就創新長效多肽藥物開發簽訂戰略合作與授權協議 石 藥 集 團 有 限 公 司（「 本 公 司 」， 連 同 其 附 屬 公 司 統 稱「 本 集 團 」）董 事 會（「 董 事 會 」）欣 然 宣 佈，本集團已與全球生物製藥領導者阿斯利康簽訂戰略研發合作與授權協議（「該協議」）， 以利用本集團專有的緩釋給藥技術平台及多肽藥物AI發現平台（「該等平台」），開發創新長 效多肽藥物。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產 生或因倚賴該等內容而引致之任何損失承擔任何責任。 CSPC PHARMACEUTICAL GROUP LIMITED 石 藥 集 團 有 限 公 司 – 2 – – 1 – 除中國內地、香港特別行政區、澳門特別行政區及台灣地區外，阿斯利康將獲得本集團每 月一次注射用體重管理產品組合的全球獨家權利，包括一個臨床準備就緒的項目SYH2082 （ 長效GLP1R / GIPR激動劑，正推進至I期臨床 ），以及三 ...

Group 1 - China and the UK have reached several cooperative outcomes, including the establishment of a financial working group and a reduction in whisky import tariffs from 10% to 5% [3][6] - The gold and silver markets have experienced significant volatility, with gold prices reaching nearly $5600 per ounce before dropping close to $5100, while silver prices fluctuated between $117 and $121 before falling below $107 [3][6] - Apple's Q1 2026 revenue grew by 16% year-on-year to $143.76 billion, with iPhone revenue at $85.27 billion and earnings per share at $2.84, both setting historical records [3][6] Group 2 - SpaceX and xAI are reportedly in talks for a merger, preparing for an IPO later this year, which would integrate Musk's various ventures into a single entity [4] - The Chinese government has introduced a plan to stimulate service consumption, outlining 12 policy measures across key sectors such as transportation and tourism [5][6] - The A-share market saw a significant rise in the liquor sector, with Kweichow Moutai's stock increasing by 8.61% in a single day [6] Group 3 - The U.S. Senate failed to advance a funding bill, putting the federal government at risk of a shutdown [17] - The global gold demand reached a record high of 5002 tons in 2025, with investment demand hitting a milestone of 2175 tons [22] - Samsung Electronics reported a 209.2% year-on-year increase in operating profit for Q4 2025, setting a new record for quarterly performance [20]

Macro Dynamics - The People's Bank of China announced that the weighted average interest rate for newly issued commercial personal housing loans will be 3.06% in Q4 2025 [2][20] - The State Council issued a work plan to accelerate the cultivation of new growth points in service consumption, focusing on optimizing service supply and enhancing consumer experience [3][21] Company Dynamics - The Beijing humanoid robot innovation center's pilot verification platform has officially launched, with an expected annual production capacity of 5,000 units [4][21] - Kunshan established an artificial intelligence industry fund with a total scale of 5 billion yuan, aiming to support local AI enterprises and ecosystem development [5][21] - Zhongtai Securities expects a net profit increase of 40% to 60% for 2025, with significant growth in wealth management and asset management [6][22] - The global largest sovereign fund, Norway's sovereign wealth fund, reported a 15.1% annual return for 2025, with stock investment returns at 19.3% [6][22] - Chao Hong Ji indicated that rising gold prices may theoretically suppress consumer demand, while also potentially stimulating jewelry demand due to investment value [11][26] - Shengyi Technology forecasts a net profit increase of 87% to 98% for 2025, driven by rising sales of copper-clad laminates [12][26] - Century Huatong anticipates a net profit increase of 357.47% to 475.34% for 2025, with continuous revenue growth over the past 12 quarters [13][27] - Hailanxin expects a net profit increase of 387.47% to 631.2% for 2025, supported by advancements in autonomous technology and key project developments [14][28] - AstraZeneca plans to invest over 100 billion yuan (approximately 15 billion USD) in China by 2030 to expand its pharmaceutical production and R&D [15][29] - Tianfu Communication completed a share reduction plan by a board member, with no impact on company governance or control [16][29] - China Gold reported that its stock trading is experiencing excessive market sentiment, which may lead to short-term price corrections [17][30] - Western Gold issued a risk warning regarding the significant price increase of gold products in the market [18][30] - Zhaojin Gold highlighted potential risks associated with its overseas mining projects and the aging of mining facilities [19][30]

Investment Rating - The report does not explicitly provide an investment rating for the rare disease industry. Core Insights - The rare disease sector is characterized by significant policy evolution and market trends, with a focus on the accessibility of treatments and the development of orphan drugs [1][2][5]. Summary by Sections Overview of the Rare Disease Industry - The report analyzes the policies regarding rare diseases in China, the United States, Japan, and Europe, highlighting the differences in definitions and management frameworks across these regions [6][12]. - China has included 207 diseases in its rare disease directory, while the U.S. has no unified directory but manages information through the GARD database [10][11]. Patient Population and Management Status - The report indicates that rare diseases affect over 200 million people globally, with China having more than 20 million affected individuals [12][14]. - The management systems in China are still developing, with significant gaps in data accuracy and epidemiological tracking compared to established systems in the U.S. and Europe [13][14]. Drug Availability and Accessibility - As of 2024, China has approved 55 rare disease drugs, while the U.S. has approved 26, and the EU has approved 15 [15][16]. - The report notes that 70.5% of rare diseases globally have available treatments, but many patients in China still face challenges in accessing these medications due to high costs and limited insurance coverage [16][17]. Leading Companies in Rare Disease Drug Development - The report identifies key players in the rare disease drug development space, emphasizing the growing pipeline of domestic research in China, although it still lags behind international pharmaceutical companies in innovation [16][17].

Investment Rating - The report maintains a "Positive" outlook for the pharmaceutical and biotechnology industry in China [6] Core Insights - The focus remains on the combination of IO (Immuno-Oncology) and ADC (Antibody-Drug Conjugates), with significant advancements expected in their joint application [10][11] - The year 2026 is identified as a critical year for the combination of IO and ADC, with expectations for increased demand for ADCs, particularly in the context of various cancer treatments [11][41] Summary by Sections Section 1: Focus on Second-Generation IO and ADC - Merck's sac-TMT is a strategic focus, with 16 ongoing Phase III clinical trials, particularly in gynecological cancers [14][15] - AstraZeneca has 8 ADCs in clinical stages, with significant data readouts expected in 2026 [19][20] - Pfizer is advancing 4 Phase III clinical trials for its PD-1/VEGF dual antibody SSGJ-707, highlighting its strategic importance in oncology [26][27] - Johnson & Johnson aims to become the leading oncology company by 2030, focusing on multiple myeloma and various cancers [30] - Bristol-Myers Squibb (BMS) is advancing its PD-L1/VEGF dual antibody and oral CELMoD therapies, with significant data catalysts expected in 2026 [32][33] - Roche is focusing on breast cancer, with its oral SERD Giredestrant expected to be approved soon [37][38] Section 2: The Year of IO+ADC Combination - The combination of IO and ADC is seen as a key development direction, with various clinical trials underway [41] - The first-generation IO+ADC combinations are competitive, with sac-TMT emerging as a significant player [42] - The second-generation IO combined with chemotherapy is led by AK112, with multiple milestones expected in the coming years [47] - The second-generation IO combined with ADC is still in early exploration, with AstraZeneca leading the way [49] Section 3: Investment Recommendations and Targets - The report identifies several investment targets, including Kangfang Biotech, 3SBio, and others, highlighting their potential in the oncology sector [11][56]